LONDON, May 2, 2026, 18:02 BST
- Halma climbed 2.72% to 4,527p on Friday, sidestepping the FTSE 100’s sluggish session.
- Cardioline has picked up Cardios from Halma, making another mark on the FTSE 100 group’s healthcare lineup.
- Focus shifts to Halma’s full-year numbers on June 11, with the company targeting mid-teens organic revenue growth and an adjusted EBIT margin around 22%.
Halma plc climbed 2.72% to 4,527p on Friday, nearly touching an all-time high. The London-listed safety and medical tech firm outperformed a weakening FTSE 100 and finished the day only 1.15% off its 52-week peak, data from MarketWatch show.
This shift hits at a key moment for Halma, as the company heads into its results period armed with a busier deal pipeline, a pricier stock, and—crucially—not much margin for error. With London markets shut over the weekend, Friday’s climb stands as the most recent signal of how much appetite investors have for one of the UK’s premium industrial tech stocks.
There’s also a subtle shift underway in Halma’s healthcare portfolio. On April 30, Cardioline—supported by healthcare investor ARCHIMED—announced it had acquired Cardios, a São Paulo-based company specializing in Holter and ambulatory blood-pressure monitors, from Halma. The financial details weren’t included in the announcement.
“This agreement boosts our leadership in telemedicine and gives us a foothold in a new region,” Cardioline CEO Luis Meireles said. For Cardios, CEO Erica Chriguer pointed to the expanded lineup, with Cardioline’s stress-test and electrocardiography offerings now part of Cardios’s suite. Cardioline
Halma’s latest sale is overshadowed by a more substantial deal announced April 13. The group revealed it was buying California’s Surgistar, a specialist in ophthalmic surgical tools, for $90 million—roughly £67 million—folding it into MicroSurgical Technology, Halma’s healthcare division.
Halma CEO Marc Ronchetti called cataract and ophthalmic surgery “long term growth markets” for the company, describing Surgistar’s offerings as “highly complementary” to MST’s portfolio. The tone stayed even, yet the takeaway is unmistakable: Halma continues to target specialty medical devices, counting on aging demographics to drive business. Halma
Competition is heating up. Revenio Group is set to buy Visionix, and Halma’s acquisition of Surgistar gives MST a bigger surgical lineup—both transactions signal more consolidation among specialist ophthalmic device makers, not the wider hospital sector.
Back in March, Halma reiterated its outlook, saying it was still heading for organic revenue growth in the mid-teens range for the year through March 31, stripping out the effects of acquisitions, disposals and currency moves. The company also stuck with its forecast for an adjusted EBIT margin around 22%.
The company reported that order intake continued to outpace both revenue and last year’s numbers. Five acquisitions have closed so far in the financial year, with a record £451 million invested on a maximum total consideration basis. Full-year results are slated for June 11.
It’s not a one-way street for Halma. With sterling gaining ground, converting overseas earnings into pounds could face some pressure, analysts say. Looking ahead, the focus is shifting toward guidance for fiscal 2027, particularly around the growth outlook for Halma’s photonics division—its light-based tech used in environmental and analytical settings.
Valuation throws up a few flags. Seventeen analysts tracked by Investing.com have pinned an average 12-month target of 4,032.65p—lower than where shares finished on Friday. Forecasts run from 3,050p all the way to 4,930p. That wide range signals some support, but also suggests the market’s already factoring in a lot of execution.
Halma still leans on its familiar formula—a collection of specialist safety, environment, and health companies, over 9,000 staffers spread across more than 20 countries, FTSE 100 status intact. This June, eyes are on whether that approach can continue to spin minor acquisitions, reliable order flow, and niche market interest into the kind of profit growth shareholders have come to expect.
